rev02_bispecific

XmAb841 (CTLA4 x LAG3)

Ongoing Phase 1 clinical study, as monotherapy and in combination with pembrolizumab (anti-PD1), for the treatment of patients with select advanced solid tumors.

Tumor infiltrating lymphocytes express multiple immune checkpoints and co-stimulatory receptors. Xencor’s bispecific tumor microenvironment (TME) activators seek to more effectively reactivate these tumor-killing T cells by engaging multiple T-cell targets simultaneously. This approach eliminates the need for the multiple antibodies and allows for more selective targeting of T cells with high checkpoint expression, which may potentially improve the therapeutic index of combination immunotherapies.

XmAb841 (previously XmAb22841) is a bispecific antibody that simultaneously targets immune checkpoint receptors CTLA-4 and LAG-3 and is designed to promote tumor-selective T-cell activation. Xencor’s XmAb® Bispecific Fc Domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on XmAb841. XmAb bispecific Fc domains have been engineered to eliminate Fc gamma receptor (FcγR) binding, with the intent to prevent activation and/or depletion of T cells via engagement by FcγR-expressing cells. In preclinical studies, XmAb841 and an anti-PD1 antibody significantly enhanced T cell proliferation and activation and anti-tumor activity in vivo.

Each of Xencor’s three bispecific TME activators tests a distinct mechanism of TME activation. Vudalimab and XmAb104 are also being evaluated in Phase 1 clinical studies.

Additional Resources